Rybrevant Plus Leclaza Has 'Very Potent Activity' in Lung Ca

Rybrevant plus Leclaza had promising response and progression-free survival rates in patients with EGFR-mutant non-small cell lung cancer.

Related Keywords

South Korea , United States , American , Byoung Chul Cho , Yonsei Cancer Center , American Society Of Clinical Oncology Annual Meeting , Clinical Oncology Annual ,